- All
- Anesthesiology
- Anti-infectives and immunology
- Biologicals
- Blood disorders
- Cardiovascular
- CNS
- Diabetes
- Endocrinology/Sexual health
- Gastrointestinal Diseases
- General modelling
- Genetic Disorders
- Lung Diseases
- Methods
- Oncology
- Paediatrics
- Pain
- Peripheral Nervous System
- Safety pharmacology
Solms A., Iorio A., Ahsman M.J., Vis P., Shah A., Berntorp E., Garmann D. Favorable Pharmacokinetic Characteristics of Extended-Half-Life Recombinant Factor VIII BAY 94-9027 Enable Robust Individual Profiling Using a Population Pharmacokinetic Approach. Clinical Pharmacokinetics 2020 [Link to publication].
Favié, L.M.A., Peeters-Scholte , C.M.P.C.D., Bakker A., Tjabbes, H., Egberts, T.C.G., Bel van, F., Rademaker C.M.A., Vis P., and Groenendaal F. Translation from animal to clinical studies, choosing the optimal moment; Comment. Pediatric Research, 2020. [Link to publication].
Mahar M.K., Yang S., Johnson B., Visser S.A.G., Berg van der P., Noort van N., Post T.M. Model- Informed Drug Development for Daprodustat Supports the Design of Individualized Dosing Regimens in Chronic Kidney Disease Patients With Anemia. Clinical Pharmacology & Therapeutics, 2025 [Link to publication].
Yassen A., Kanefendt F., Zisowsky J.m Broeker A., Mundl H., Vis P., Garmann D., Berkhout J. Population Pharmacokinetics of Asundexian in People at Risk for thromboembolic/Cardiovascular Events. CPT: Pharmacometrics & Systems Pharmacology, 2025. [Link to publication].
Wu Y., Völler S., Goulooze S.C., Allegaert K., Sherwin C.M.T., vanRongen A., Roofthooft D.W.E., Simons S.H.P., Tibboel D., Flint R.B., Anker van den J.N., and Knibbe D.A.J. A Novel Maturation Equation for Hepatic Clearance Across Preterm, Term Neonates, Children, and Adults: Application toParacetamol and Its Metabolite. The Journal of Clinical Pharmacology, 2025 . [Link to publication].
Bosch R., Petrone M., Arends R., Sijbrands E.J.G., Hoefman S., Snelder N. From In Vitro Efficacy to Long-Term HbA1c Response for GLP-1R/GlucagonR Agonism Using the 4GI-HbA1c Systems Model. CPT: PSP, 2025. [Link to publication].
Muliaditana M., Steeg van T.J., Averyb L.B., Sunb W., Hammondc T.R., Hijdra D., Choid S., Pillaie N., Leksa N.C., and Mavroudis P.D. Translational minimal physiologically based pharmacokinetic model for transferrin receptor-mediated brain delivery of antibodies. MABS [Link to publication].
Vos E.M., Peeters-Scholte C.M.P.C.D., Boiten J., Hund H.M., Jellema K., Kloppenborg R.P., Ghariq E., Es van A.C.G.M., Venema E., Lingsma H.F., A. Hoeven van der E.S., Vis P.W., Dippel D.W.J., Roozenbeek B. Wijngaard I.R. Safety, Tolerability, and Pharmacokinetics of the Neuroprotectant 2-Iminobiotin in Patients With Large-Vessel Occlusion Ischemic Stroke Treated With Endovascular Thrombectomy. Stroke, 2025 [Link to publication].
Mulder M.B., Noort van M., Man de R.A., Kamar N., Bruijne de J., Knoester M., Blokzijl H., Vanwolleghem T., Roosens L., Izopet J., Gandia P., Eijk van der A.A., Metselaar H.,J., Ahsman M.J., Steeg van T.J., Hesselink D.A. and Winter de B.C.M. Development of a ribavirin dosing regimen in transplant recipients with chronic hepatitis E virus infection: a population pharmacokinetic and -dynamic model. J Antimicrob Chemother, 2025 [Link to publication].
Goulooze S.C., Krekels E.H.J., Knibbe C.A.J., Noort van M. The Drug Titration Paradox in the Presence of Intra‑Individual Variation: Can we Estimate the True Concentration‑Effect Relationship? The AAPS Journal 2025 [Link to publication].
Rietveld P.C.S., Koolen S.L.W., Zeiser S., Rijcken C.J.F., Noort van M., Eerden van R.A.G., Atrafi F., Miedema I.H.C., Oordt van C.W.M.H., Mathijssen R.H.J., Snelder N., Sassen S.D.T. Drug release from docetaxel-entrapped core-crosslinked polymeric micelles: A population pharmacokinetic modelling approach based on clinical data. Biomedicine & Pharmacotherapy 2025. [Link to publication].
DeJong J., Cadogan E., Davies M., Ramos-Montoya A., Smith A., Steeg van T.J., Richards R. Defining preclinical efficacy with the DNAPK inhibitor AZD7648 in combination with olaparib: a minimal systems pharmacokinetic–pharmacodynamic model. Journal of Pharmacokinetics and Pharmacodynamics 2025 [Link to publication].
Goulooze S.C., Muliaditan M., Franzese R.C., Mantero A., Visser S.A.G., Melhem M., Post T.M., Rathi C., Struemper H. Tutorial on Conditional Simulations With a Tumor Size-Overall Survival Model to Support Oncology Drug Development. CPT: Pharmacometrics & Systems Pharmacology, 2025 [Link to publication].
Struemper H., Rathi C., Muliaditan M., Goulooze S.C., Franzese R.C., Mantero A., Melhem M., Post T.M., Visser S.A.G. Development of a Joint Tumor Size–Overall Survival Modeling and Simulation Framework Supporting Oncology Development Decision-Making. CPT: Pharmacometrics & Systems Pharmacology, 2025 [Link to publication].
Binazon O., Cocco M., Thwaites D., Cooper C., Moshir M., Vanhoenacker P., Defever D., Sompel van der A., Steeland S., Pynaert G., Ulrichts P., Baumeister J. Effects of efgartigimod treatment on humoral and cellular immune responses: analysis of T-cell-dependent antibody response in cynomolgus monkeys. Journal of Immunotoxicology 2025 [Link to publication].